{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:52:03Z","timestamp":1772787123504,"version":"3.50.1"},"reference-count":60,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["24-44-00004"],"award-info":[{"award-number":["24-44-00004"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["KP-06-H41\/3"],"award-info":[{"award-number":["KP-06-H41\/3"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["KP-06-H39\/7"],"award-info":[{"award-number":["KP-06-H39\/7"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bulgarian National Science Fund","award":["24-44-00004"],"award-info":[{"award-number":["24-44-00004"]}]},{"name":"Bulgarian National Science Fund","award":["KP-06-H41\/3"],"award-info":[{"award-number":["KP-06-H41\/3"]}]},{"name":"Bulgarian National Science Fund","award":["KP-06-H39\/7"],"award-info":[{"award-number":["KP-06-H39\/7"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background\/Objectives: New anti-tuberculosis compounds are needed to treat patients infected with multi- or extensively drug-resistant Mycobacterium tuberculosis strains. Studies based on spontaneous in vitro mutagenesis can provide insights into the possible modes of action and resistance mechanisms of such new compounds. We evaluated the primary response of M. tuberculosis in vitro to the action of new aroylhydrazones and nitrofuroylamides. Methods: The reference strain H37Rv was cultured on solid media with compounds at increased concentrations relative to MIC. Resistant clones were investigated using whole-genome sequencing and bioinformatics tools to assess the role and potential impact of identified mutations. Results: Some of the mutations are significant (based on in silico analysis), located in essential genes, and therefore of particular interest. Frameshift mutations were observed in (i) Rv2702\/ppgK, which is associated with starvation-induced drug tolerance and persistence in mice, and (ii) Rv3696c\/glpK, which has been described as a switch on\/off mutation associated with drug tolerance. Nonsynonymous substitutions were found in Rv0506\/mmpS2, which belongs to the Mmp protein family involved in transport and drug efflux, and in infB, encoding the translation initiation factor IF-2. Conclusions: The primary adaptation of M. tuberculosis to the selective pressure of the tested compounds is complex and multifaceted. It involves multiple unrelated genes and pathways linked to non-specific drug tolerance, efflux systems, or mechanisms counteracting oxidative stress.<\/jats:p>","DOI":"10.3390\/antibiotics14030225","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:47:17Z","timestamp":1740379637000},"page":"225","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genomic Insight into Primary Adaptation of Mycobacterium tuberculosis to Aroylhydrazones and Nitrofuroylamides In Vitro"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5924-0576","authenticated-orcid":false,"given":"Igor","family":"Mokrousov","sequence":"first","affiliation":[{"name":"St. Petersburg Pasteur Institute, 197101 St. Petersburg, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violina T.","family":"Angelova","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Medical University, 1000 Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivaylo","family":"Slavchev","sequence":"additional","affiliation":[{"name":"Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail V.","family":"Bezruchko","sequence":"additional","affiliation":[{"name":"St. Petersburg Pasteur Institute, 197101 St. Petersburg, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simeon","family":"Dimitrov","sequence":"additional","affiliation":[{"name":"The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9679-2791","authenticated-orcid":false,"given":"Dmitrii E.","family":"Polev","sequence":"additional","affiliation":[{"name":"St. Petersburg Pasteur Institute, 197101 St. Petersburg, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0437-2162","authenticated-orcid":false,"given":"Georgi M.","family":"Dobrikov","sequence":"additional","affiliation":[{"name":"Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violeta","family":"Valcheva","sequence":"additional","affiliation":[{"name":"The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.bmcl.2016.11.084","article-title":"Recent advancements in the development of anti-tuberculosis drugs","volume":"27","author":"Chetty","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cmi.2021.08.007","article-title":"Pretomanid for tuberculosis: A systematic review","volume":"28","author":"Gils","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"116785","DOI":"10.1016\/j.ejmech.2024.116785","article-title":"Recent advances and challenges of revolutionizing drug-resistant tuberculosis treatment","volume":"277","author":"Wei","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.bmcl.2018.12.053","article-title":"Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent","volume":"29","author":"Kumar","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e0047423","DOI":"10.1128\/aac.00474-23","article-title":"Discovery and characterization of antimycobacterial nitro-containing compounds with distinct mechanisms of action and in vivo efficacy","volume":"67","author":"Eke","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Mokrousov, I., Slavchev, I., Solovieva, N., Dogonadze, M., Vyazovaya, A., Valcheva, V., Masharsky, A., Belopolskaya, O., Dimitrov, S., and Zhuravlev, V. (2022). Molecular Insight into Mycobacterium tuberculosis Resistance to Nitrofuranyl Amides Gained through Metagenomics-like Analysis of Spontaneous Mutants. Pharmaceuticals, 15.","DOI":"10.3390\/ph15091136"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Elsaman, T., Mohamed, M.S., and Mohamed, M.A. (2019). Current development of 5-nitrofuran-2-yl derivatives as antitubercular agents. Bioorg. Chem., 88.","DOI":"10.1016\/j.bioorg.2019.102969"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ejmech.2018.06.033","article-title":"Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agents","volume":"155","author":"Chiarelli","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ddr.21872","article-title":"Conventional and microwave-assisted organic synthesis of novel antimycobacterial agents bearing furan and pyridine hybrids","volume":"83","author":"Desai","year":"2022","journal-title":"Drug. Dev. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2298\/JSC230424040K","article-title":"Synthesis, antimycobacterial, and antifungal evaluation of new 4-(furan-2-ylmethyl)-6-methylpyridazin-3 (2H)-ones","volume":"89","author":"Karayavuz","year":"2024","journal-title":"J. Serb. Chem. Soc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ijbiomac.2021.11.017","article-title":"Identification of diphenyl furan derivatives via high throughput and computational studies as ArgA inhibitors of Mycobacterium tuberculosis","volume":"193","author":"Khurana","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.4155\/fmc-2023-0110","article-title":"Synthesis of novel furan-based chalcone derivatives as anti-tuberculosis agents: In vitro, cytotoxicity assessment and in silico","volume":"15","author":"Dhivya","year":"2023","journal-title":"Future Med. Chem."},{"key":"ref_13","first-page":"78","article-title":"Synthesis and Anti-Tuberculosis Activity of Substituted 3,4-(dicoumarin-3-yl)-2,5-diphenyl Furans and Pyrroles","volume":"31","author":"Jadhav","year":"2023","journal-title":"Eng. Proc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2174\/0929867054546654","article-title":"Recent advances in new structural classes of anti-tuberculosis agents","volume":"12","author":"Nayyar","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2174\/1871526515666150724104411","article-title":"Hydrazones as a privileged structural linker in antitubercular agents: A review","volume":"15","author":"Mathew","year":"2015","journal-title":"Infect. Disord. Drug Targets"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"112035","DOI":"10.1016\/j.ejmech.2020.112035","article-title":"Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors","volume":"188","author":"Krishna","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"102545","DOI":"10.1016\/j.tube.2024.102545","article-title":"Preclinical tests for salicylhydrazones derivatives to explore their potential for new antituberculosis agents","volume":"148","author":"Ieque","year":"2024","journal-title":"Tuberculosis"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"de Faria, C.F., Moreira, T., Lopes, P., Costa, H., Krewall, J.R., Barton, C.M., Santos, S., Goodwin, D., Machado, D., and Viveiros, M. (2021). Designing new antitubercular isoniazid derivatives with improved reactivity and membrane trafficking abilities. Biomed. Pharmacother., 144.","DOI":"10.1016\/j.biopha.2021.112362"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.2174\/1381612043383214","article-title":"Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis","volume":"10","author":"Barry","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1021\/jm501029r","article-title":"Design, synthesis, and evaluation of new thiadiazole-based direct inhibitors of enoyl acyl carrier protein reductase (InhA) for the treatment of tuberculosis","volume":"58","author":"Turk","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Haiba, N.S., Khalil, H.H., Moniem, M.A., El-Wakil, M.H., Bekhit, A.A., and Khattab, S.N. (2019). Design, synthesis and molecular modeling studies of new series of s-triazine derivatives as antimicrobial agents against multi-drug resistant clinical isolates. Bioorg. Chem., 89.","DOI":"10.1016\/j.bioorg.2019.103013"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Popio\u0142ek, \u0141. (2021). Updated Information on Antimicrobial Activity of Hydrazide-Hydrazones. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179389"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Dimitrov, S., Slavchev, I., Simeonova, R., Mileva, M., Pencheva, T., Philipov, S., Georgieva, A., Tsvetanova, E., Teneva, Y., and Rimpova, N. (2023). Evaluation of Acute and Sub-Acute Toxicity, Oxidative Stress and Molecular Docking of Two Nitrofuranyl Amides as Promising Anti-Tuberculosis Agents. Biomolecules, 13.","DOI":"10.3390\/biom13081174"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00044-019-02293-w","article-title":"New indole and indazole derivatives as potential antimycobacterial agents","volume":"28","author":"Angelova","year":"2019","journal-title":"Med. Chem. Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Angelova, V.T., Pencheva, T., Vassilev, N., K-Yovkova, E., Mihaylova, R., Petrov, B., and Valcheva, V. (2022). Development of New Antimycobacterial Sulfonyl Hydrazones and 4-Methyl-1,2,3-thiadiazole-Based Hydrazone Derivatives. Antibiotics, 11.","DOI":"10.3390\/antibiotics11050562"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Valcheva, V., Simeonova, R., Mileva, M., Philipov, S., Petrova, R., Dimitrov, S., Georgieva, A., Tsvetanova, E., Teneva, Y., and Angelova, V.T. (2022). In Vivo Toxicity, Redox-Modulating Capacity and Intestinal Permeability of Novel Aroylhydrazone Derivatives as Anti-Tuberculosis Agents. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15010079"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S2666-5247(20)30031-8","article-title":"Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: A phenotypic and phylogenetic analysis","volume":"1","author":"Nimmo","year":"2020","journal-title":"Lancet Microbe"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/cid\/ciad596","article-title":"Genotype-Phenotype Characterization of Serial Mycobacterium tuberculosis Isolates in Bedaquiline-Resistant Tuberculosis","volume":"78","author":"Brown","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.cmi.2020.08.030","article-title":"Frequent acquisition of bedaquiline resistance by epidemic extensively drug-resistant Mycobacterium tuberculosis strains in Russia during long-term treatment","volume":"27","author":"Mokrousov","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ijantimicag.2014.12.026","article-title":"The new tuberculosis drug Perchlozone\u00ae shows cross-resistance with thiacetazone","volume":"45","author":"Gopal","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e0064524","DOI":"10.1128\/aac.00645-24","article-title":"Loss of glycerol catabolism confers carbon-source-dependent artemisinin resistance in Mycobacterium tuberculosis","volume":"68","author":"Martini","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Shi, J., Liu, Y., Wu, T., Li, L., Han, S., Peng, X., Shang, Y., Guo, Y., Pang, Y., and Gao, M. (2023). Spontaneous mutational patterns and novel mutations for bedaquiline and clofazimine resistance in Mycobacterium tuberculosis. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.00090-23"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"de Oliveira, M.C.B., and Balan, A. (2020). The ATP-Binding Cassette (ABC) Transport Systems in Mycobacterium tuberculosis: Structure, Function, and Possible Targets for Therapeutics. Biology, 9.","DOI":"10.3390\/biology9120443"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Minato, Y., Gohl, D.M., Thiede, J.M., Chac\u00f3n, J.M., Harcombe, W.R., Maruyama, F., and Baughn, A.D. (2019). Genomewide Assessment of Mycobacterium tuberculosis Conditionally Essential Metabolic Pathways. mSystems, 4.","DOI":"10.1128\/mSystems.00070-19"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"DeJesus, M.A., Gerrick, E.R., Xu, W., Park, S.W., Long, J.E., Boutte, C.C., Rubin, E.J., Schnappinger, D., Ehrt, S., and Fortune, S.M. (2017). Comprehensive Essentiality Analysis of the Mycobacterium tuberculosis Genome via Saturating Transposon Mutagenesis. mBio, 8.","DOI":"10.1128\/mBio.02133-16"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Griffin, J.E., Gawronski, J.D., Dejesus, M.A., Ioerger, T.R., Akerley, B.J., and Sassetti, C.M. (2011). High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1002251"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-2958.2003.03425.x","article-title":"Genes required for mycobacterial growth defined by high density mutagenesis","volume":"48","author":"Sassetti","year":"2003","journal-title":"Mol. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"19665","DOI":"10.1073\/pnas.1907631116","article-title":"Phase variation in Mycobacterium tuberculosis glpK produces transiently heritable drug tolerance","volume":"116","author":"Safi","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"12989","DOI":"10.1073\/pnas.2134250100","article-title":"Genetic requirements for mycobacterial survival during infection","volume":"100","author":"Sassetti","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Marrero, J., Trujillo, C., Rhee, K.Y., and Ehrt, S. (2013). Glucose phosphorylation is required for Mycobacterium tuberculosis persistence in mice. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003116"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e0069922","DOI":"10.1128\/msystems.00699-22","article-title":"Mycobacterium tuberculosis Requires the Outer Membrane Lipid Phthiocerol Dimycocerosate for Starvation-Induced Antibiotic Tolerance","volume":"8","author":"Block","year":"2023","journal-title":"mSystems"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/j.1365-2958.2003.03922.x","article-title":"The principal sigma factor sigA mediates enhanced growth of Mycobacterium tuberculosis in vivo","volume":"51","author":"Wu","year":"2004","journal-title":"Mol. Microbiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"106384","DOI":"10.1016\/j.micpath.2023.106384","article-title":"Overexpression of a membrane transport system MSMEG_1381 and MSMEG_1382 confers multidrug resistance in Mycobacterium smegmatis","volume":"185","author":"Salini","year":"2023","journal-title":"Microb. Pathog."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Narang, A., Garima, K., Porwal, S., Bhandekar, A., Shrivastava, K., Giri, A., Sharma, N.K., Bose, M., and Varma-Basil, M. (2019). Potential impact of efflux pump genes in mediating rifampicin resistance in clinical isolates of Mycobacterium tuberculosis from India. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0223163"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2147\/IDR.S346724","article-title":"Diversity of glpK Gene and Its Effect on Drug Sensitivity in Mycobacterium bovis","volume":"15","author":"Dong","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Shell, S.S., Prestwich, E.G., Baek, S.H., Shah, R.R., Sassetti, C.M., Dedon, P.C., and Fortune, S.M. (2013). DNA methylation impacts gene expression and ensures hypoxic survival of Mycobacterium tuberculosis. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003419"},{"key":"ref_47","first-page":"108444","article-title":"Code inside the codon: The role of synonymous mutations in regulating splicing machinery and its impact on disease","volume":"790","author":"Sarkar","year":"2022","journal-title":"Mutat. Res. Mol. Mech. Mutagen."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e2405510121","DOI":"10.1073\/pnas.2405510121","article-title":"Synonymous codon substitutions modulate transcription and translation of a divergent upstream gene by modulating antisense RNA production","volume":"121","author":"Rodriguez","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Bailey, S.F., Alonso Morales, L.A., and Kassen, R. (2021). Effects of Synonymous Mutations beyond Codon Bias: The Evidence for Adaptive Synonymous Substitutions from Microbial Evolution Experiments. Genome Biol. Evol., 13.","DOI":"10.1093\/gbe\/evab141"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Wang, B.W., Zhu, J.H., and Javid, B. (2020). Clinically relevant mutations in mycobacterial LepA cause rifampicin-specific phenotypic resistance. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-65308-2"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Fishbein, S.R.S., Tomasi, F.G., Wolf, I.D., Dulberger, C.L., Wang, A., Keshishian, H., Wallace, L., Carr, S.A., Ioerger, T.R., and Rego, E.H. (2020). The conserved translation factor LepA is required for optimal synthesis of a porin family in Mycobacterium smegmatis. J. Bacteriol., 203.","DOI":"10.1128\/JB.00604-20"},{"key":"ref_52","first-page":"359","article-title":"RbfA and IF3 couple ribosome biogenesis and translation initiation to increase stress tolerance","volume":"48","author":"Sharma","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Tauc, M., Cougnon, M., Carcy, R., Melis, N., Hauet, T., Pellerin, L., Blondeau, N., and Pisani, D.F. (2021). The eukaryotic initiation factor 5A (eIF5A1), the molecule, mechanisms and recent insights into the pathophysiological roles. Cell Biosci., 11.","DOI":"10.1186\/s13578-021-00733-y"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1021\/bi400191z","article-title":"The crystal structure of Mycobacterium tuberculosis NrdH at 0.87 \u00c5 suggests a possible mode of its activity","volume":"52","author":"Phulera","year":"2013","journal-title":"Biochemistry"},{"key":"ref_55","first-page":"127","article-title":"Redox Proteins of Mycobacterium tuberculosis","volume":"94","author":"Phulera","year":"2014","journal-title":"J. Indian Inst. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Sugandhi, S., Rajmane, V., Taunk, K., Jadhav, S., Nema, V., Rapole, S., and Mande, S.C. (2023). The role of thioredoxin proteins in Mycobacterium tuberculosis probed by proteome-wide target profiling. Biochem. Biophys. Rep., 35.","DOI":"10.1016\/j.bbrep.2023.101512"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/j.1365-2958.2005.04510.x","article-title":"The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol","volume":"55","author":"Colangeli","year":"2005","journal-title":"Mol. Microbiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1247136","DOI":"10.1126\/science.1247136","article-title":"ESCRT machinery is required for plasma membrane repair","volume":"343","author":"Jimenez","year":"2014","journal-title":"Science"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1128\/AAC.47.11.3616-3619.2003","article-title":"Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: Rapid, simple, and inexpensive method","volume":"47","author":"Martin","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Ignatov, K.B., Blagodatskikh, K.A., Shcherbo, D.S., Kramarova, T.V., Monakhova, Y.A., and Kramarov, V.M. (2019). Fragmentation Through Polymerization (FTP): A new method to fragment DNA for next-generation sequencing. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210374"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/3\/225\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:40:28Z","timestamp":1760028028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/3\/225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["antibiotics14030225"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14030225","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]}}}